Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
This research aims to provide continued treatment to participants with cancer who are still receiving study therapy in a Genentech or F. Hoffmann-La Roche sponsored trial and who lack local access to these treatments. It involves an open-label, multicenter extension phase where eligible patients can continue on investigational therapies following their original study. Participants will continue receiving Roche investigational medicinal products IMPs either as monotherapy or combined with other agents, following the dosing, schedule, and administration used in their parent study. Treatment can continue until disease progression, loss of clinical benefit, unacceptable toxicity, pregnancy, non-compliance, local treatment availability, withdrawal, or study termination by the sponsor. Throughout the study, participants will be monitored for ongoing access to the study drugs and for adverse events using standardized criteria over approximately 10 years. Safety and clinical benefit assessments will guide continuation. The study offers long-term observation to evaluate treatment continuation and tolerability, with participation lasting until one of the stopping criteria is met or up to the study end date.